(2S)-2-methoxy-3-[4-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]cyclopenta[b]thiopyran-7-yl]propanoic acid

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: (2S)-2-methoxy-3-[4-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]cyclopenta[b]thiopyran-7-yl]propanoic acid
• 化学式: C₂₄H₂₃NO₅S
• 分子量: 437.5
• InChiKey: HPLGCMNBPBZOFO-NRFANRHFSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.8
• 重原子数：
  31
• 可旋转键数：
  9
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  110
• 氢给体数：
  1
• 氢受体数：
  7

文献信息

• SUBSTITUTED PHENYLCYCLOHEXYLGLYCOLATES
  申请人：Gant Thomas G.

  公开号：US20090247628A1

  公开（公告）日：2009-10-01

  Disclosed herein are substituted phenylcyclohexylglycolate-based muscarinic acetylcholine receptor modulators of Formula I, processes of preparation thereof, pharmaceutical compositions thereof, and methods of use thereof.

  本文揭示了基于取代苯基环己基甘醇酸酯的 Formula I 的肌氨酸乙酰胆碱受体调节剂，其制备方法、药物组合物及使用方法。
• [EN] SOLID STATE FORMS OF ALEGLITAZAR SODIUM<br/>[FR] FORMES À L'ÉTAT SOLIDE D'ALEGLITAZAR SODIQUE
  申请人：RATIOPHARM GMBH

  公开号：WO2013181384A1

  公开（公告）日：2013-12-05

  The present invention provides solid state forms of Aleglitazar sodium, processes for preparing the solid state forms, and pharmaceutical compositions comprising the solid state forms.

  本发明提供了阿列格利他唑钠的固态形式，制备这些固态形式的方法，以及包含这些固态形式的药物组合物。
• Pharmaceutical compositions for combination therapy
  申请人：Intercept Pharmaceuticals, Inc.

  公开号：US11311557B2

  公开（公告）日：2022-04-26

  The present invention relates to a pharmaceutical composition comprising a combination of an FXR agonist and at least one lipid lowering agent (e.g., PPAR-alpha agonist, PPAR-delta agonist, PPAR-alpha and delta dual agonist, and/or statin). Also disclosed is use of the combination for the treatment or prevention of a FXR mediated disease or condition, such as primary biliary cirrhosis (PBC), primary sclerosing cholangitis (PSC), portal hypertension, bile acid diarrhea, NAFLD (nonalcoholic fatty liver disease), NASH (non-alcohol-induced steatohepatitis), and other chronic liver diseases. The combination of the present invention is useful for the treatment or prevention of conditions related to elevated lipid and liver enzyme levels. The present invention also relates to packs or kits including the pharmaceutical combination.

  本发明涉及一种药物组合物，该组合物包含一种FXR激动剂和至少一种降脂药（如PPAR-α激动剂、PPAR-δ激动剂、PPAR-α和δ双重激动剂和/或他汀类药物）的组合。本发明的组合物还可用于治疗或预防 FXR 介导的疾病或病症，如原发性胆汁性肝硬化 (PBC)、原发性硬化性胆管炎 (PSC)、门静脉高压症、胆汁酸腹泻、非酒精性脂肪肝 (NAFLD)、非酒精性脂肪性肝炎 (NASH) 和其他慢性肝病。本发明的组合物可用于治疗或预防与血脂和肝酶水平升高有关的疾病。本发明还涉及包括该药物组合的包装或试剂盒。
• PHARMACEUTICAL COMPOSITIONS FOR COMBINATION THERAPY
  申请人：Intercept Pharmaceuticals, Inc.

  公开号：EP3253382B1

  公开（公告）日：2021-11-17
• DIFFERENTIATION INTO BROWN ADIPOCYTES
  申请人：THE GENERAL HOSPITAL CORPORATION

  公开号：US20150004144A1

  公开（公告）日：2015-01-01

  The technology described herein is directed to methods and compositions relating to the differentiation and activity of brown adipocytes, and the therapeutic uses thereof.